Cullinan Oncology LLC

Stock Chart, Company Information, and Scan Results

$7.93(as of Aug 27, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Cullinan Oncology LLC Company Information, Fundamentals, and Technical Indicators

Stock Price$7.93
Ticker SymbolCGEM
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees111
CountyUSA
Market Cap$451.3M
EBIDTA-234.4M
10-Day Moving Average7.73
P/E Ratio-2.26
20-Day Moving Average7.65
Forward P/E Ratio6.30
50-Day Moving Average7.77
Earnings per Share-3.16
200-Day Moving Average9.37
Profit Margin-Infinity%
RSI52.82
Shares Outstanding59.1M
ATR0.41
52-Week High19.89
Volume414,501
52-Week Low6.85
Most Recent Support Level7.50
Book Value492.1M
Most Recent Resistance Level8.32
P/B Ratio0.95
Upper Keltner8.58
P/S RatioInfinity
Lower Keltner6.72
Debt-to-Equity Ratio8.58
Next Earnings Date11/06/2025
Cash Surplus44.8M
Next Ex-Dividend DateUnknown

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a monoclonal antibody in Phase 1 trial for the treatment of solid tumors and multiple myeloma. Its development products also include CLN-049, a humanized bispecific antibody in Phase 1 trial for the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome, as well as measurable residual disease positive AML; and CLN-617, a fusion protein in Phase 1 trial for the treatment of solid tumors. It has a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Cullinan Oncology LLC In Our Stock Scanner

As of Aug 28, 2025
example chart graphic
Scan Name: Morning StarScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Heikin Ashi BreakoutScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.